EN
icon
CN
CN | EN
Our Science
EpimAb's Proprietary Bispecific Platform : FIT-Ig®
Similar manufacturing convenience to monoclonal antibodies
Solubility comparable to monoclonal antibodies
Widely applicable to
multiple targets
Preserve the functions and properties of the monoclonal antibody
Tissue penetration
similar to monoclonal
antibodies
Production convenience
similar to monoclonal
antibodies
Pipeline
We have a robust and sustainable pipeline with 4 clinical stage assets (EMB-01, EMB-02 , EMB-06 and EMB-09) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint inhibitors, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
EMB-02
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in several GI indications in the U.S. and China.
EGFR/cMET Gastrointestinal cancers
EMB-06
EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells or the depletion B cells. At 2025 ASH conference, the positive phase I results for EMB-06 in multiple myeloma was presented as an oral presentation. In September 2024, based on its superior efficacy/safety profile, the right of ex-China of EMB-06 was licensed out to Vignette Bio, which is later acquired by Candid Therapeutics.
BCMA/CD3 Multiple myeloma /autoimmune
EMB-07
EMB-07 is a T cell engaging bispecific antibody targeting a novel tumor associated antigen ROR1. EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. EMB-07 is undergoing phase I trials.
ROR1/CD3 Solid tumors /hematologic malignancies
EMB-09
EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally activate T effector cells by stimulating OX40 through PD-L1 dependent cross linking. EMB-09 showed superior immune cell activation in comparison with the mAb combinations. Its unique OX40 binding epitope could improve the therapeutic window, and silenced Fc effector function can avoid T effector cell depletion.
PD-L1/OX40 Solid tumor
News
2025-04-01
EpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting
2025-02-27
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
2024-12-16
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
Who We Are
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with research and manufacturing facilities in Shanghai and Suzhou. With our unique and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that is able to generate bispecific molecules with antibody-like properties, we are creating a pipeline of novel therapeutics focused around immuno-oncology and other disease areas with high unmet need.
EpimAb people
Platform Introduction
Management Team
Company Culture
Partnering Strategy
Contact
Shanghai
Adress
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road, Zhangjiang High-tech Park, Shanghai, 201204, China
Phone
+86-21-61951000
Email
contact@epimab.com
shanghai